EA200700886A1 - Соединение тиадиазола и его применение - Google Patents

Соединение тиадиазола и его применение

Info

Publication number
EA200700886A1
EA200700886A1 EA200700886A EA200700886A EA200700886A1 EA 200700886 A1 EA200700886 A1 EA 200700886A1 EA 200700886 A EA200700886 A EA 200700886A EA 200700886 A EA200700886 A EA 200700886A EA 200700886 A1 EA200700886 A1 EA 200700886A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tiadiazole
connection
application
treatment
relates
Prior art date
Application number
EA200700886A
Other languages
English (en)
Other versions
EA012181B1 (ru
Inventor
Кингпинг Зенг
Гуомин Йао
Джордж Эрих Волхитер
Велларкад Н. Висванадхан
Эндрю Таскер
Джеймс Томас Райдер
Хольгер Моненшайн
Селиа Домингэз
Мэттью Пол Бурбо
Original Assignee
Амген Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Амген Инк. filed Critical Амген Инк.
Publication of EA200700886A1 publication Critical patent/EA200700886A1/ru
Publication of EA012181B1 publication Critical patent/EA012181B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C07D285/13—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433—Thidiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C07D285/125—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Изобретение относится к тиадиазольным соединениям, пригодным для лечения заболеваний, опосредованных протеинкиназой В (РКВ). Изобретение также относится к терапевтическому применению таких тиадиазольных соединений и их композиций в лечении болезненных состояний, связанных с аномальным ростом клетки, раком, воспалением и нарушением обмена веществ.
EA200700886A 2004-10-18 2005-10-18 Соединения тиадиазола и их применение EA012181B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US61901004P 2004-10-18 2004-10-18
PCT/US2005/037374 WO2006044860A2 (en) 2004-10-18 2005-10-18 Thiadiazole compounds and methods of use

Publications (2)

Publication Number Publication Date
EA200700886A1 true EA200700886A1 (ru) 2008-02-28
EA012181B1 EA012181B1 (ru) 2009-08-28

Family

ID=36203652

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200700886A EA012181B1 (ru) 2004-10-18 2005-10-18 Соединения тиадиазола и их применение

Country Status (15)

Country Link
US (3) US7354944B2 (ru)
EP (1) EP1809282B1 (ru)
JP (1) JP4931823B2 (ru)
KR (1) KR20070073791A (ru)
CN (1) CN101389335A (ru)
AU (1) AU2005295441B2 (ru)
BR (1) BRPI0516609A (ru)
CA (1) CA2583217C (ru)
EA (1) EA012181B1 (ru)
ES (1) ES2400689T3 (ru)
IL (1) IL182203A0 (ru)
MA (1) MA29029B1 (ru)
MX (1) MX2007004551A (ru)
WO (1) WO2006044860A2 (ru)
ZA (1) ZA200703975B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4931823B2 (ja) * 2004-10-18 2012-05-16 アムジエン・インコーポレーテツド チアジアゾール化合物及び使用方法
WO2007007054A1 (en) * 2005-07-08 2007-01-18 Cancer Research Technology Limited Phthalamides, succinimides and related compounds and their use as pharmaceuticals
CA2636077C (en) * 2006-01-18 2012-01-03 Amgen Inc. Thiazole compounds as protein kinase b (pkb) inhibitors
DE102006030479A1 (de) * 2006-07-01 2008-03-20 Merck Patent Gmbh Indazolderivate
WO2008016123A1 (fr) * 2006-08-03 2008-02-07 Takeda Pharmaceutical Company Limited INHIBITEUR DE LA GSK-3β
DE102007002717A1 (de) 2007-01-18 2008-07-24 Merck Patent Gmbh Heterocyclische Indazolderivate
DE102007022565A1 (de) 2007-05-14 2008-11-20 Merck Patent Gmbh Heterocyclische Indazolderivate
US8648069B2 (en) 2007-06-08 2014-02-11 Abbvie Inc. 5-substituted indazoles as kinase inhibitors
CA2693473A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Thiadiazole modulators of pkb
CA2692713A1 (en) 2007-07-17 2009-01-22 Amgen Inc. Heterocyclic modulators of pkb
DE102008038222A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Indazol-5-carbonsäurehydrazid-derivate
DE102008038220A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh Oxadiazolderivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
WO2010083246A1 (en) * 2009-01-15 2010-07-22 Amgen Inc. Fluoroisoquinoline substituted thiazole compounds and methods of use
JO2998B1 (ar) 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
MX352672B (es) 2011-09-27 2017-12-04 Amgen Inc Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer.
MY174339A (en) 2012-08-13 2020-04-09 Novartis Ag 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions
US9040712B2 (en) 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
AU2014219075C1 (en) 2013-02-19 2018-09-06 Amgen Inc. Cis-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer
US9758495B2 (en) 2013-03-14 2017-09-12 Amgen Inc. Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
JOP20200296A1 (ar) 2013-06-10 2017-06-16 Amgen Inc عمليات صنع وأشكال بلورية من mdm2 مثبط
PL3027600T3 (pl) 2013-07-31 2022-08-08 Novartis Ag 1,4-dwupodstawione pochodne pirydazyny i ich zastosowanie do leczenia stanów związanych z niedoborem smn
US20160287569A1 (en) 2013-11-11 2016-10-06 Amgen Inc. Combination therapy including an mdm2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers
SG11201605014YA (en) 2013-12-19 2016-07-28 Actelion Pharmaceuticals Ltd Antibacterial 1h-indazole and 1h-indole derivatives
RU2624857C1 (ru) * 2016-01-26 2017-07-07 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Фармацевтическая композиция с противогрибковой активностью и способ ее получения
WO2017151409A1 (en) 2016-02-29 2017-09-08 University Of Florida Research Foundation, Incorporated Chemotherapeutic methods
WO2018013430A2 (en) 2016-07-12 2018-01-18 Arisan Therapeutics Inc. Heterocyclic compounds for the treatment of arenavirus infection
JOP20190272A1 (ar) 2017-05-22 2019-11-21 Amgen Inc مثبطات kras g12c وطرق لاستخدامها
GB2587457B (en) 2017-08-04 2022-06-01 Skyhawk Therapeutics Inc Methods and compositions for modulating splicing
JP7150823B2 (ja) 2017-09-08 2022-10-11 アムジエン・インコーポレーテツド ＫＲａｓ Ｇ１２Ｃの阻害剤及びそれを使用する方法
US10342786B2 (en) 2017-10-05 2019-07-09 Fulcrum Therapeutics, Inc. P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD
SG10202110259QA (en) 2017-10-05 2021-10-28 Fulcrum Therapeutics Inc Use of p38 inhibitors to reduce expression of dux4
US11090304B2 (en) 2018-05-04 2021-08-17 Amgen Inc. KRAS G12C inhibitors and methods of using the same
JP7377679B2 (ja) 2018-11-19 2023-11-10 アムジエン・インコーポレーテツド がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法
KR20210135241A (ko) 2019-02-05 2021-11-12 스카이호크 테라퓨틱스, 인코포레이티드 스플라이싱을 조절하는 방법 및 조성물
EP3920928A4 (en) 2019-02-06 2022-09-28 Skyhawk Therapeutics, Inc. METHODS AND COMPOSITIONS FOR MODULATION OF SPLICING
EP3738593A1 (en) 2019-05-14 2020-11-18 Amgen, Inc Dosing of kras inhibitor for treatment of cancers
SG11202112855WA (en) 2019-05-21 2021-12-30 Amgen Inc Solid state forms
WO2021076655A1 (en) 2019-10-15 2021-04-22 Amgen Inc. Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers
WO2021126816A1 (en) 2019-12-16 2021-06-24 Amgen Inc. Dosing regimen of a kras g12c inhibitor

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3904756A (en) 1966-12-23 1975-09-09 American Cyanamid Co Substituted nitroimidazolyl thiadiazoles and oxadiazoles as antibacterial agents and growth promoting compounds
US3666860A (en) 1966-12-23 1972-05-30 Gerald Berkelhammer Substituted nitroimidazolylthiadiazoles and oxadiazoles as antiprotozoal agents
US3991200A (en) 1974-04-25 1976-11-09 American Cyanamid Company Substituted nitroimidazolyl thiadiazoles and oxadiazoles as antibacterial agents and growth promoting compounds
US3452035A (en) 1966-12-23 1969-06-24 American Cyanamid Co 2 - amino - 5 - (5 - nitro - 1 - substituted-2 - imidazolyl) - 1,3,4 - thiadiazoles and oxadiazoles
US3830924A (en) 1966-12-23 1974-08-20 American Cyanamid Co Substituted nitroimidazolyl-thiadiazoles as growth promoting agents
US3740434A (en) 1966-12-23 1973-06-19 American Cyanamid Co Substituted nitroimidazolylthiadiazoles and oxadiazoles as antiprotozoal agents
US3842174A (en) 1966-12-23 1974-10-15 American Cyanamid Co Substituted nitroimidazolylthiadiazoles and oxadiazoles as antiprotozoal agents
US3666830A (en) * 1971-01-21 1972-05-30 Gen Electric Lead compound catalyzed siloxane resin system
US4086238A (en) 1976-06-21 1978-04-25 Velsicol Chemical Corporation 1-Thiadiazolyl-4-methoxymethyl-5-hydroxyimidazolidinones
DE2640601C2 (de) 1976-09-09 1985-11-28 Agfa-Gevaert Ag, 5090 Leverkusen Farbphotographisches Material mit 2-Äquivalent-Gelbkupplern
DE3407505A1 (de) 1984-03-01 1985-09-05 A. Nattermann & Cie GmbH, 5000 Köln Neue benzothiazin-carbonsaeureamide mit antiarthritischer wirksamkeit
FR2572074B1 (fr) 1984-10-18 1987-07-17 Sanofi Sa Derives du thiadiazole actifs sur le systeme nerveux central, procede d'obtention et compositions pharmaceutiques les contenant
FR2636628B1 (fr) * 1988-08-25 1990-12-28 Sanofi Sa Derives du thiadiazole-1,3,4, leur procede d'obtention et compositions pharmaceutiques en contenant
AU3934693A (en) 1992-03-26 1993-10-21 Dowelanco N-heterocyclic nitro anilines as fungicides
JPH08151364A (ja) 1994-02-18 1996-06-11 Nissan Chem Ind Ltd 含窒素環状化合物および除草剤
WO1996038419A1 (fr) 1995-05-31 1996-12-05 Nissan Chemical Industries, Ltd. Derives de 5-pyrazolecarboxamide et agent de lutte contre les maladies des plantes
WO1997022360A2 (en) 1995-12-20 1997-06-26 Medical Research Council Control of protein synthesis, and screening method for agents
US20050053594A1 (en) 1995-11-16 2005-03-10 Dario Alessi RAC-PK as a therapeutic agent or in diagnostics, screening method for agents and process for activating RAC-PK
WO1999031096A1 (en) 1997-12-18 1999-06-24 Shaman Pharmaceuticals, Inc. Piperazine derivatives useful as hypoglycemic agents
ATE284412T1 (de) 1998-01-09 2004-12-15 Univ Arizona State Anti-kryptokokkus peptide
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6852752B2 (en) 1999-12-17 2005-02-08 Vicuron Pharmaceuticals Inc. Urea compounds, compositions and methods of use and preparation
CA2393825A1 (en) 1999-12-17 2001-06-21 Versicor, Inc. Novel succinate compounds, compositions and methods of use and preparation
US6797820B2 (en) 1999-12-17 2004-09-28 Vicuron Pharmaceuticals Inc. Succinate compounds, compositions and methods of use and preparation
US6420400B1 (en) 2000-04-07 2002-07-16 Kinetek Pharmaceuticals, Inc. Antiproliferative 1,2,3-thiadiazole compounds
AR032653A1 (es) 2001-02-09 2003-11-19 Telik Inc Inhibidores heterociclicos del trasportador de glicina 2 composiciones farmaceuticas, uso y metodos.
WO2002083064A2 (en) 2001-04-10 2002-10-24 Merck & Co., Inc. A method of treating cancer
FR2832713B1 (fr) * 2001-11-23 2004-02-13 Sanofi Synthelabo Derives de 4-(1,3,4-thiadiazol-2-yl)-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
AU2003226301A1 (en) 2002-04-08 2003-10-20 Merck And Co., Inc. Method of treating cancer
KR20050006237A (ko) * 2002-05-06 2005-01-15 버텍스 파마슈티칼스 인코포레이티드 티아디아졸 또는 옥사디아졸 및 ｊａｋ 단백질 키나제억제제로서의 이들의 용도
US7300933B2 (en) 2002-05-07 2007-11-27 Neurosearch A/S Diazabicyclic biaryl derivatives
GB0218625D0 (en) 2002-08-10 2002-09-18 Astex Technology Ltd Pharmaceutical compounds
DE60311853T2 (de) * 2002-09-30 2007-06-21 Neurosearch A/S Neue 1,4-diazabicycloalkanderivate, deren herstellung und verwendung
EP1410844A1 (en) * 2002-10-15 2004-04-21 Centre National De La Recherche Scientifique (Cnrs) Silicon-based porous catalytic system for oligomerising light olefins
US20040102360A1 (en) 2002-10-30 2004-05-27 Barnett Stanley F. Combination therapy
TW200416221A (en) * 2002-10-30 2004-09-01 Vertex Pharma Compositions useful as inhibitors of ROCK and other protein kinases
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
US20050004186A1 (en) * 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
ATE512957T1 (de) 2003-04-24 2011-07-15 Merck Sharp & Dohme Hemmer der akt aktivität
WO2005014554A1 (en) 2003-08-08 2005-02-17 Astex Therapeutics Limited 1h-indazole-3-carboxamide compounds as mapkap kinase modulators
ATE536353T1 (de) 2003-08-20 2011-12-15 Vertex Pharma 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazol- verbindungen als protein kinase inhibitoren
WO2005020991A1 (en) 2003-08-21 2005-03-10 Pfizer Products, Inc. Compounds for the treatment of neurodegenerative disorders
US20050143384A1 (en) 2003-10-30 2005-06-30 Eric Sartori Amide thiadiazole inhibitors of plasminogen activator inhibitor-1
EP1682123A1 (en) 2003-11-07 2006-07-26 SmithKline Beecham (Cork) Limited Cancer treatment method
CN101389345A (zh) 2004-03-19 2009-03-18 宾州研究基金会 治疗黑素瘤的组合方法和组合物
US7232820B2 (en) 2004-04-01 2007-06-19 Pfizer Inc Thiadiazole-amine compounds for the treatment of neurodegenerative disorders
WO2005113762A1 (en) 2004-05-18 2005-12-01 Pfizer Products Inc. CRYSTAL STRUCTURE OF PROTEIN KINASE B-α (AKT-1) AND USES THEREOF
US7893020B2 (en) 2004-05-21 2011-02-22 Mpex Pharmaceuticals, Inc. Bacterial efflux pump inhibitors and methods of treating bacterial infections
EA200700140A1 (ru) * 2004-07-16 2007-08-31 Янссен Фармацевтика Н.В. Димерные соединения пиперидина, пиперазина или морфолина или их семичленные аналоги, предназначенные для лечения нейродегенеративных нарушений
JP4931823B2 (ja) 2004-10-18 2012-05-16 アムジエン・インコーポレーテツド チアジアゾール化合物及び使用方法
CA2584838A1 (en) 2004-10-20 2006-05-04 Neurosearch A/S Novel diazabicyclic aryl derivatives and their medical use
CA2636077C (en) 2006-01-18 2012-01-03 Amgen Inc. Thiazole compounds as protein kinase b (pkb) inhibitors
US20080242694A1 (en) 2006-09-18 2008-10-02 D Sidocky Neil R Amino-substituted heterocycles, compositions thereof, and methods of treatment therewith

Also Published As

Publication number Publication date
JP2008516986A (ja) 2008-05-22
JP4931823B2 (ja) 2012-05-16
ES2400689T3 (es) 2013-04-11
US7700636B2 (en) 2010-04-20
US7919514B2 (en) 2011-04-05
AU2005295441A1 (en) 2006-04-27
CA2583217C (en) 2011-05-31
MX2007004551A (es) 2007-05-23
EP1809282B1 (en) 2013-01-09
IL182203A0 (en) 2007-07-24
ZA200703975B (en) 2009-01-28
CA2583217A1 (en) 2006-04-27
US20080255145A1 (en) 2008-10-16
EP1809282A2 (en) 2007-07-25
KR20070073791A (ko) 2007-07-10
BRPI0516609A (pt) 2008-04-29
US7354944B2 (en) 2008-04-08
EA012181B1 (ru) 2009-08-28
US20060154961A1 (en) 2006-07-13
EP1809282A4 (en) 2009-11-25
WO2006044860A3 (en) 2007-07-05
CN101389335A (zh) 2009-03-18
MA29029B1 (fr) 2007-11-01
AU2005295441B2 (en) 2009-04-23
US20080269243A1 (en) 2008-10-30
WO2006044860A2 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
EA200700886A1 (ru) Соединение тиадиазола и его применение
EA200801716A1 (ru) Тиазольные соединения и их применение
WO2009011880A3 (en) Heterocyclic modulators of pkb
WO2009011871A3 (en) Thiadiazole modulators of pkb
EA200501607A1 (ru) Замещённые фенилалкановые кислоты
EA201492082A1 (ru) Кристаллические формы ингибитора тирозинкиназы брутона
TW200630327A (en) Substituted phenylalkanoic acids
TW200509910A (en) Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists
EA201290964A1 (ru) Пептидные конъюгаты агонистов рецептора glp-1 и их применение
EA200970835A1 (ru) Индазолы, применяемые для лечения расстройств, опосредуемых эстрогеновым рецептором бета
WO2020252397A8 (en) Small molecule proteolysis-targeting chimeras and methods of use thereof
NO20084652L (no) Deazapuriner anvendelige som inhibitorer av januskinaser
EA201001532A1 (ru) Соединения фенилзамещенного 2-имино-3-метилпирролопиримидинона в качестве ингибиторов bace-1, композиции и их применение
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
TW200732347A (en) VEGF analogs and methods of use
ATE323705T1 (de) Substituierte indolizinähnliche verbindungen und ihre verwendung
EA201070035A1 (ru) Модулирующие сиртуин соединения
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
NO20082508L (no) Aminopyrimidiner anvendelige som kinaseinhibitorer
EA200600414A1 (ru) ПРОИЗВОДНЫЕ БОРОНОВОЙ КИСЛОТЫ (ВАРИАНТЫ), ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ, КОМПОЗИЦИЯ ДЛЯ ИНГИБИРОВАНИЯ АКТИВНОСТИ NF-kB И ДЕГРАДАЦИИ БЕЛКА И СПОСОБЫ ЛЕЧЕНИЯ ЗАБОЛЕВАНИЙ (ВАРИАНТЫ)
EA200501710A1 (ru) Замещённые карбоновые кислоты
EA200901133A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
BRPI0410905A (pt) inibidores de p-38
ATE372324T1 (de) Substituierte heteroarylverbindungen als inhibitoren von proteintyrosinphosphatasen
EA201000797A1 (ru) Аминотриазолы в качестве ингибиторов pi3k

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU